
Aurobindo Pharma's subsidiary, Eugia Pharma Specialities, has gained USFDA approval to produce and sell a generic version of Icatibant injection, used to treat hereditary angioedema. The approved product matches Takeda Pharmaceuticals' FIRAZYR, with a strength of 30 mg/3 mL. The launch is planned for September 2023. The estimated market size for this product, based on IQVIA data, is about USD 137 million for the year ending June 2023.
Like
Save
Share